Topsalysin

Drug Profile

Topsalysin

Alternative Names: PRX-302; PSA-PA 1; PSA-PAH 1

Latest Information Update: 26 May 2017

Price : $50

At a glance

  • Originator Johns Hopkins University; University of Victoria
  • Developer Sophiris Bio
  • Class Antineoplastics; Bacterial toxins; Pore forming cytotoxic proteins
  • Mechanism of Action Apoptosis stimulants; Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Benign prostatic hyperplasia
  • Phase II Prostate cancer

Most Recent Events

  • 01 Mar 2017 Phase-II clinical trials in Prostate cancer (In adults, In the elderly) in United Kingdom, USA (Intraprostatic) (NCT03081481)
  • 15 Dec 2016 Biomarkers information updated
  • 09 Jun 2016 Sophiris Bio completes a phase IIa trial in Prostate cancer in United Kingdom (NCT02499848) prior to June 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top